TET2 and cancer: Our finding that TET2 expression, in the context of high MYC expression, negatively correlates with the mRNA levels of several lysosomal genes in breast tumors suggests that treatments combining autophagy inducers with DNA hypomethylating agents such as decitabine and/or TET-activating molecules could be beneficial to cancer patients.